New Pharmaceuticals market report from Global Markets Direct: "Bial - Portela & Ca, S.A. - Product Pipeline Review - 2012"

Boston, MA -- (SBWire) -- 10/29/2012 --Global Market Direct's pharmaceuticals report, "Bial - Portela & Ca, S.A. - Product Pipeline Review - 2012" provides data on the Bial - Portela & Ca, S.A.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Bial - Portela & Ca, S.A.'s corporate website, SEC filings, investor presentations and featured press releases, both from Bial - Portela & Ca, S.A. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Bial - Portela & Ca, S.A. - Brief Bial - Portela & Ca, S.A. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Bial - Portela & Ca, S.A. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Bial - Portela & Ca, S.A. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Bial - Portela & Ca, S.A.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get this Report

- Evaluate Bial - Portela & Ca, S.A.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Bial - Portela & Ca, S.A. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Bial - Portela & Ca, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Bial - Portela & Ca, S.A..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Bial - Portela & Ca, S.A. and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Transgene SA - Product Pipeline Review - 2012
- Neuralgia - Pipeline Review, H1 2012
- NovImmune SA - Product Pipeline Review - 2012
- Sanofi Pasteur SA - Product Pipeline Review - 2012
- Evolva SA - Product Pipeline Review - 2012
- AC Immune SA - Product Pipeline Review - 2012
- BioAlliance Pharma SA - Product Pipeline Review - 2012
- Cytheris SA - Product Pipeline Review - 2012
- Med Discovery SA - Product Pipeline Review - 2012
- Cardio3 BioSciences SA - Product Pipeline Review - 2012